Literature DB >> 15170211

Acute myeloid leukemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity.

Kristin J Hope1, Liqing Jin, John E Dick.   

Abstract

Emerging evidence suggests cancer stem cells sustain neoplasms; however, little is understood of the normal cell initially targeted and the resultant cancer stem cells. We show here, by tracking individual human leukemia stem cells (LSCs) in nonobese diabetic-severe combined immunodeficiency mice serially transplanted with acute myeloid leukemia cells, that LSCs are not functionally homogeneous but, like the normal hematopoietic stem cell (HSC) compartment, comprise distinct hierarchically arranged LSC classes. Distinct LSC fates derived from heterogeneous self-renewal potential. Some LSCs emerged only in recipients of serial transplantation, indicating they divided rarely and underwent self-renewal rather than commitment after cell division within primary recipients. Heterogeneity in LSC self-renewal potential supports the hypothesis that they derive from normal HSCs. Furthermore, normal developmental processes are not completely abolished during leukemogenesis. The existence of multiple stem cell classes shows the need for LSC-targeted therapies.

Entities:  

Mesh:

Year:  2004        PMID: 15170211     DOI: 10.1038/ni1080

Source DB:  PubMed          Journal:  Nat Immunol        ISSN: 1529-2908            Impact factor:   25.606


  293 in total

Review 1.  The role of epigenetic regulation in stem cell and cancer biology.

Authors:  Lilian E van Vlerken; Elaine M Hurt; Robert E Hollingsworth
Journal:  J Mol Med (Berl)       Date:  2012-06-02       Impact factor: 4.599

Review 2.  Cancer stem cells: a stride towards cancer cure?

Authors:  Amitava Sengupta; Jose A Cancelas
Journal:  J Cell Physiol       Date:  2010-10       Impact factor: 6.384

Review 3.  The difficulty of targeting cancer stem cell niches.

Authors:  Mark A LaBarge
Journal:  Clin Cancer Res       Date:  2010-06-08       Impact factor: 12.531

Review 4.  The biology of head and neck cancer stem cells.

Authors:  Zhaocheng Zhang; Manoel Sant'Ana Filho; Jacques E Nör
Journal:  Oral Oncol       Date:  2011-11-08       Impact factor: 5.337

5.  Adoptive transfer of PR1 cytotoxic T lymphocytes associated with reduced leukemia burden in a mouse acute myeloid leukemia xenograft model.

Authors:  Qing Ma; Changqing Wang; Dan Jones; Kathryn E Quintanilla; Dan Li; Yang Wang; Eric D Wieder; Karen Clise-Dwyer; Gheath Alatrash; You Mj; Mark F Munsell; Sijie Lu; Muzaffar H Qazilbash; Jeffrey J Molldrem
Journal:  Cytotherapy       Date:  2010-08-24       Impact factor: 5.414

Review 6.  The cancer stem cell paradigm: a new understanding of tumor development and treatment.

Authors:  Johnathan D Ebben; Daniel M Treisman; Michael Zorniak; Raman G Kutty; Paul A Clark; John S Kuo
Journal:  Expert Opin Ther Targets       Date:  2010-06       Impact factor: 6.902

Review 7.  [Tumor stem cell research - basis and challenge for diagnosis and therapy].

Authors:  Heidrun Karlic; Harald Herrmann; Axel Schulenburg; Thomas W Grunt; Sylvia Laffer; Irina Mirkina; Rainer Hubmann; Medhat Shehata; Brigitte Marian; Edgar Selzer; Michael Pfeilstöcker; Elisabeth Pittermann; Ulrich Jäger; Hubert Pehamberger; Christoph Zielinski; Peter Valent
Journal:  Wien Klin Wochenschr       Date:  2010-07-22       Impact factor: 1.704

8.  Functional Niche Competition Between Normal Hematopoietic Stem and Progenitor Cells and Myeloid Leukemia Cells.

Authors:  Chen Glait-Santar; Ronan Desmond; Xingmin Feng; Taha Bat; Jichun Chen; Elisabeth Heuston; Benjamin Mizukawa; James C Mulloy; David M Bodine; Andre Larochelle; Cynthia E Dunbar
Journal:  Stem Cells       Date:  2015-10-05       Impact factor: 6.277

Review 9.  TIM-3 as a novel therapeutic target for eradicating acute myelogenous leukemia stem cells.

Authors:  Yoshikane Kikushige; Toshihiro Miyamoto
Journal:  Int J Hematol       Date:  2013-09-18       Impact factor: 2.490

10.  Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemia.

Authors:  Takayo Sasaki; Juan Carlos Rivera-Mulia; Daniel Vera; Jared Zimmerman; Sunny Das; Michelle Padget; Naoto Nakamichi; Bill H Chang; Jeff Tyner; Brian J Druker; Andrew P Weng; Curt I Civin; Connie J Eaves; David M Gilbert
Journal:  Exp Hematol       Date:  2017-04-19       Impact factor: 3.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.